JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Radiofrequency Ablation in Treating Colorectal Cancer Patients with Liver Metastases
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Radiofrequency Ablation in Treating Colorectal Cancer Patients with Liver Metastases
Xu, Chuan; Huang, Xin-En; Lv, Peng-Hua; Wang, Shu-Xiang; Sun, Ling; Wang, Fu-An;
  PDF(new window)
 Abstract
Purpose: To evaluate efficacy of radiofrequency ablation (RFA) in treating colorectal cancer patients with liver metastases. Methods: During January 2010 to April 2012, 56 colorectal cancer patients with liver metastases underwent RFA. CT scans were obtained one month after RFA for all patients to evaluate tumor response. (CR+PR+SD)/n was used to count the disease control rates (DCR). Survival data of 1, 2 and 3 years were obtained from follow up. Results: Patients were followed for 10 to 40 months after RFA (mean time, ). Median survival time was 27 months. The 1, 2, 3 year survival rate were 80.4%, 71.4%, 41%, 1 % respectively. 3-year survival time for patients with CR or PR after RFA was 68.8% and 4.3% respectively, the difference was statistically significant. The number of CR, PR, SD and PD in our study was 13, 23, 11 and 9 respectively. Conclusions: RFA could be an effective method for treating colorectal cancer patients with liver metastases, and prolong survival time, especially for metastatic lesions less than or equal to 3 cm. But this result should be confirmed by randomized controlled studies.
 Keywords
Radiofrequency ablation;colorectal liver metastases-survival time;
 Language
English
 Cited by
1.
Transarterial Chemoembolization Monotherapy in Combination with Radiofrequency Ablation or Percutaneous Ethanol Injection for Hepatocellular Carcinoma,;;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 9, pp.4349-4352 crossref(new window)
 References
1.
Babawale SN, Jensen TM, Frokjar JB (2015). Long-term survival following radiofrequency ablation of colorectal liver metastases: A retrospective study. World J Gastrointest Surg, 7, 33-38. crossref(new window)

2.
Bruix J, Sherman M, Llovet JM, et al (2001). Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the study of the Liver. J Hepatol, 35, 421-30. crossref(new window)

3.
Burrel M, Reig M, Forner A, et al (2012). Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol, 56, 1330-35. crossref(new window)

4.
Chinn SB, Lee FT, Kennedy, et al (2001). Effect of vascular occlusion on radfiofrequency ablation of the liver: Results in a porcine model. AJR Am J Roentgenol, 176, 789-95. crossref(new window)

5.
Germani G, Pleguezuelo M, Gurusamy, et al (2010). Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular: a meta-analysis. J Hepatol, 52, 380-87. crossref(new window)

6.
Gillams AR, Lees WR (2009). Five-year survival in 309 patients with colorectal liver metastases terated with radiofrequency ablation. Eur Radiol, 19, 1206-13. crossref(new window)

7.
Hagness M, Foss A, Line PD (2013). Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg, 257, 800-806. crossref(new window)

8.
Hsu CY, Huang YH, Chiou YY, et al (2011). Comparision of radiofrequency ablation and transterial chemoembolization for hepatocellular carcinoma within the Milan criterial: a propensity score analysis. Liver Transpl, 17, 556-66. crossref(new window)

9.
Riaz A, Lewandowski RJ, Kulik L, et al (2010). Radiologicpathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol, 33, 1143-52. crossref(new window)

10.
Mckay A, Dixon E, Taylor M, et al (2006). Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg, 93, 1192-1201. crossref(new window)

11.
Nicholl MB, Bilchik AJ (2008). Thermal ablation of hepatic malignancy: Useful but still not optimal. Eur J Surg, 34, 318-23. crossref(new window)

12.
Pathak S, Jones R, Tang JM, et al (2011). Ablative therapies for colorectal liver metastases: a systematic reviev. Colorectal Dis, 13, 252-65. crossref(new window)

13.
Wilson TR, Fridlyand J, Yan Y, et al (2012). Widespread potential for growth-factor-driven resistence to anticancer kinase inhibitors. Nature, 487, 505-9. crossref(new window)